Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study-Reference-Cited by-同舟云学术

Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study

Published:2018-04 Issue:4 Volume:18 Page:441-451
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Ladhani Shamez N,Collins Sarah,Djennad Abdelmajid,Sheppard Carmen L,Borrow Ray,Fry Norman K,Andrews Nicholas J,Miller Elizabeth,Ramsay Mary E

Funder

Pfizer

GlaxoSmithKline

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference28 articles.

1. Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales;Andrews;PLoS One,2011

2. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study;Andrews;Lancet Infect Dis,2014

3. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study;Flasche;PLoS Med,2011

4. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England;Van Hoek;Vaccine,2014

5. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study;Miller;Lancet Infect Dis,2011

Cited by 427 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older;Vaccine;2024-11

2. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina;Vaccine;2024-10

3. Aktuelle und neue Impfstoffe gegen Pneumokokken;Die Innere Medizin;2024-09-02

4. Long-term effect of pneumococcal conjugate vaccines on invasive pneumococcal disease incidence among people of all ages from national, active, laboratory-based surveillance in South Africa, 2005–19: a cohort observational study;The Lancet Global Health;2024-09

5. Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study;The Lancet Public Health;2024-09